Skip to main content

Replimune Group, Inc. (REPL)

NASDAQ: REPL · IEX Real-Time Price · USD
29.22 0.12 (0.41%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap1.37B
Revenue (ttm)n/a
Net Income (ttm)-72.66M
Shares Out46.89M
EPS (ttm)-1.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume204,545
Open29.21
Previous Close29.10
Day's Range28.42 - 29.68
52-Week Range26.57 - 46.64
Beta2.37
AnalystsBuy
Price Target53.78 (+84.1%)
Earnings DateNov 4, 2021

About REPL

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, wh...

IndustryBiotechnology
IPO DateJul 20, 2018
CEOphilip Astley-Sparke
Employees152
Stock ExchangeNASDAQ
Ticker SymbolREPL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for REPL stock is "Buy." The 12-month stock price forecast is 53.78, which is an increase of 84.05% from the latest price.

Price Target
$53.78
(84.05% upside)
Analyst Consensus: Buy

News

Replimune Appoints Christy Oliger to its Board of Directors

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy pla...

6 days ago - GlobeNewsWire

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE anti-P...

1 month ago - GlobeNewsWire

Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...

2 months ago - GlobeNewsWire

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, wi...

4 months ago - GlobeNewsWire

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today anno...

4 months ago - GlobeNewsWire

Replimune to Present at the William Blair Biotech Focus Conference 2021

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today anno...

5 months ago - GlobeNewsWire

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expan...

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs

6 months ago - GlobeNewsWire

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update

Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma

6 months ago - GlobeNewsWire

Replimune Appoints Tanya Lewis as Chief Development Operations Officer

WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...

6 months ago - GlobeNewsWire

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination w...

WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...

7 months ago - GlobeNewsWire

Replimune to Host Virtual Investor Event on June 3, 2021

Event to begin at 8:00 AM ET Event to begin at 8:00 AM ET

7 months ago - GlobeNewsWire

Analysts See Plenty of Upside for Replimune

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Other symbols:AMGNBMYREGNSNY
7 months ago - GuruFocus

Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American...

Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2

7 months ago - GlobeNewsWire

3 Biotech Stocks That Could Double In 12 Months

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...

Other symbols:FGENIMTX
8 months ago - Benzinga

Replimune to Present at the American Association for Cancer Research Annual Meeting 2021

WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

8 months ago - GlobeNewsWire

Replimune to Present at Three Upcoming Investor Conferences

WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...

9 months ago - GlobeNewsWire

Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference

WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...

9 months ago - GlobeNewsWire

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across al...

10 months ago - GlobeNewsWire

2 Biotech Stocks That Could Have Tripled Your Money This Year

One has a better chance to keep climbing than the other does.

Other symbols:SURF
1 year ago - The Motley Fool

2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now

Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.

Other symbols:SRRK
1 year ago - The Motley Fool

Replimune Announces Pricing of Upsized Public Offering

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced t...

1 year ago - GlobeNewsWire

Replimune Announces Proposed Public Offering

BOSTON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a...

1 year ago - GlobeNewsWire

Replimune Releases Updated Corporate Presentation

WOBURN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced ...

1 year ago - GlobeNewsWire

Replimune Appoints Tanya Lewis to the Board of Directors

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...

1 year ago - GlobeNewsWire

Why Replimune Stock Is Soaring Today

The company plans to present encouraging early-stage clinical data at a major conference next month.

1 year ago - The Motley Fool